Where is the live CopyMark page for USPTO serial 79440218?

The live record is at https://getcopymark.com/trademark/79440218. Use https://getcopymark.com/trademark/{serialNumber} for any 8-digit USPTO serial.

Who owns SERUM INSTITUTE?

According to the public USPTO record for serial number 79440218, the listed owner(s) include: SERUM INSTITUTE OF INDIA PRIVATE LIMITED.

What is USPTO serial number 79440218?

Serial number 79440218 is the USPTO application identifier for the mark SERUM INSTITUTE. It is used to track examination, publication, and registration of this trademark.

What is the current status of SERUM INSTITUTE?

SERUM INSTITUTE (79440218) currently shows USPTO status code 661 on the public record. This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Which trademark classes cover SERUM INSTITUTE?

The public record lists International Classes: 005. Each class corresponds to categories of goods or services identified in the application or registration.

Trademark: SERUM INSTITUTE Serial# 79440218 | status 661; last event TEME | Trademark Info & Attorney Guidance

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with SERUM INSTITUTE?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner

Monitor this mark, or talk with CopyMark about this registration.

Trademark Monitoring

(312) 319-4460

Not the owner?

File a new U.S. trademark application, or speak with our attorneys.

Start a new application

(312) 319-4460

Owner

SERUM INSTITUTE OF INDIA PRIVATE LIMITED
IN
Other trademarks owned by SERUM INSTITUTE OF INDIA PRIVATE LIMITED

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Michele S. Katz

Michele S. Katz Advitam IP, LLC150 S. WACKER DRIVE, SUITE 2400CHICAGO, IL 60606United States

Goods and services

Class	Description	Status	First use
005	Pharmaceutical preparations for human use for use in the treatment of Haemorrhage from varices, ulcers, Metabolism, Carnitine deficiency, Cancer, Pain and inflammation, Nausea, Vomiting, Indigestion, Iron deficiency anaemia, Bleeding in gastrointestinal and urogenital systems, abdominal and pelvic area, Uterine bleeding, Infertility, Hyperprolactinaemic disorders, Endometriosis, Benign breast disease, Menorrhagia, Gynaecomastia, Secondary amenorrhoea, Endometriosis, Menstrual cycle, Preterm birth and recurrent miscarriage, Luteal phase defect, Natural or artificial menopause, Central precocious puberty, Diabetes; Contraceptive	ACTIVE	—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Date	Code	Event	What it means
Sep 8, 2026	TEME	TEAS/EMAIL CORRESPONDENCE ENTERED	—
Sep 8, 2026	CRFA	CORRESPONDENCE RECEIVED IN LAW OFFICE	—
Sep 8, 2026	TROA	TEAS RESPONSE TO OFFICE ACTION RECEIVED	This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Mar 26, 2026	RFNT	REFUSAL PROCESSED BY IB	—
Mar 7, 2026	RFCS	NON-FINAL ACTION MAILED - REFUSAL SENT TO IB	—
Mar 7, 2026	RFRR	REFUSAL PROCESSED BY MPU	—
Feb 6, 2026	RFCR	NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW	—
Feb 5, 2026	CNRT	NON-FINAL ACTION WRITTEN	A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jan 21, 2026	DOCK	ASSIGNED TO EXAMINER	—
Jan 20, 2026	MAFR	APPLICATION FILING RECEIPT MAILED	—
Jan 20, 2026	NWOS	NEW APPLICATION OFFICE SUPPLIED DATA ENTERED	—
Jan 18, 2026	LIMI	LIMITATION FROM ORIGINAL APPLICATION ENTERED	—
Dec 25, 2025	REPR	SN ASSIGNED FOR SECT 66A APPL FROM IB	—

SERUM INSTITUTE